Chadi Nabhan, Chief Medical Officer and Head of Strategy at Ryght, shared a post on LinkedIn:
“One of the first Heme/Onc Grand Rounds I attended as a fellow over two decades ago was titled ‘Why RAS is undruggable?’
Over the past few years, scientists have proven the opposite, and today’s press release by Revolution Medicines is another feather in the cap of this chapter. A much welcome news that we must celebrate.
Looking forward to seeing more of the data – it’s a great day for patients, families, researchers, precision medicine, and the broader oncology community.”
Title: Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
Other articles featuring Chadi Nabhan on OncoDaily.